Cargando…

Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure

BACKGROUND: The primary goal of this study was to characterize the clinical outcomes of adult patients with hematologic malignancies (HM) who were treated with extracorporeal membrane oxygenation (ECMO) support when conventional treatments failed. METHODS: In this retrospective, observational study...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Sungbin, Cho, Won Chul, Lim, Ju Yong, Kang, Pil Je
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society for Thoracic and Cardiovascular Surgery 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383857/
https://www.ncbi.nlm.nih.gov/pubmed/30834214
http://dx.doi.org/10.5090/kjtcs.2019.52.1.25
_version_ 1783396904492597248
author Cho, Sungbin
Cho, Won Chul
Lim, Ju Yong
Kang, Pil Je
author_facet Cho, Sungbin
Cho, Won Chul
Lim, Ju Yong
Kang, Pil Je
author_sort Cho, Sungbin
collection PubMed
description BACKGROUND: The primary goal of this study was to characterize the clinical outcomes of adult patients with hematologic malignancies (HM) who were treated with extracorporeal membrane oxygenation (ECMO) support when conventional treatments failed. METHODS: In this retrospective, observational study at a tertiary medical center, we reviewed the clinical course of 23 consecutive patients with HM requiring ECMO who were admitted to the intensive care unit at Asan Medical Center from March 2010 to April 2015. RESULTS: A total of 23 patients (8 female; median age, 44 years; range, 29–51 years) with HM and severe acute circulatory and/or respiratory failure received ECMO therapy during the study period. Fourteen patients received veno-arterial ECMO, while 9 patients received veno-venous ECMO. The median ECMO duration was 104.7 hours (range, 37.1–221 hours). Nine patients were successfully weaned from ECMO. The in-hospital mortality rate was 91.1% (21 of 23). There were complications in 3 patients (cannulation site bleeding, limb ischemia, and gastrointestinal bleeding). CONCLUSION: ECMO is a useful treatment for patients with circulatory and/or pulmonary failure. However, in patients with HM, the outcomes of ECMO treatment results were very poor, so it is advisable to carefully decide whether to apply ECMO to these patients.
format Online
Article
Text
id pubmed-6383857
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Korean Society for Thoracic and Cardiovascular Surgery
record_format MEDLINE/PubMed
spelling pubmed-63838572019-03-04 Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure Cho, Sungbin Cho, Won Chul Lim, Ju Yong Kang, Pil Je Korean J Thorac Cardiovasc Surg Clinical Research BACKGROUND: The primary goal of this study was to characterize the clinical outcomes of adult patients with hematologic malignancies (HM) who were treated with extracorporeal membrane oxygenation (ECMO) support when conventional treatments failed. METHODS: In this retrospective, observational study at a tertiary medical center, we reviewed the clinical course of 23 consecutive patients with HM requiring ECMO who were admitted to the intensive care unit at Asan Medical Center from March 2010 to April 2015. RESULTS: A total of 23 patients (8 female; median age, 44 years; range, 29–51 years) with HM and severe acute circulatory and/or respiratory failure received ECMO therapy during the study period. Fourteen patients received veno-arterial ECMO, while 9 patients received veno-venous ECMO. The median ECMO duration was 104.7 hours (range, 37.1–221 hours). Nine patients were successfully weaned from ECMO. The in-hospital mortality rate was 91.1% (21 of 23). There were complications in 3 patients (cannulation site bleeding, limb ischemia, and gastrointestinal bleeding). CONCLUSION: ECMO is a useful treatment for patients with circulatory and/or pulmonary failure. However, in patients with HM, the outcomes of ECMO treatment results were very poor, so it is advisable to carefully decide whether to apply ECMO to these patients. The Korean Society for Thoracic and Cardiovascular Surgery 2019-02 2019-02-05 /pmc/articles/PMC6383857/ /pubmed/30834214 http://dx.doi.org/10.5090/kjtcs.2019.52.1.25 Text en Copyright © 2019 by The Korean Society for Thoracic and Cardiovascular Surgery. All rights Reserved. This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Research
Cho, Sungbin
Cho, Won Chul
Lim, Ju Yong
Kang, Pil Je
Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure
title Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure
title_full Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure
title_fullStr Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure
title_full_unstemmed Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure
title_short Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure
title_sort extracorporeal life support in adult patients with hematologic malignancies and acute circulatory and/or respiratory failure
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383857/
https://www.ncbi.nlm.nih.gov/pubmed/30834214
http://dx.doi.org/10.5090/kjtcs.2019.52.1.25
work_keys_str_mv AT chosungbin extracorporeallifesupportinadultpatientswithhematologicmalignanciesandacutecirculatoryandorrespiratoryfailure
AT chowonchul extracorporeallifesupportinadultpatientswithhematologicmalignanciesandacutecirculatoryandorrespiratoryfailure
AT limjuyong extracorporeallifesupportinadultpatientswithhematologicmalignanciesandacutecirculatoryandorrespiratoryfailure
AT kangpilje extracorporeallifesupportinadultpatientswithhematologicmalignanciesandacutecirculatoryandorrespiratoryfailure